cyrilzakka/clinical-trials huggingface dataset:
Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19

The severe acute respiratory syndrome induced by the new coronavirus (SARS-CoV-2) has been declared a worldwide pandemic. Identifying common characteristics of the disease is crucial to promote a better prognosis for patients and to reduce the occurrence of medical complications, the time to medical discharge and mortality rates. Muscle mass and strength are recognized predictive measures of medical complications and mortality in different populations, but it is still unclear whether these also applies to patients with SARS-CoV-2. Therefore, this study will investigate whether muscle mass and/or muscle strength are predictors of the time until medical discharge of patients hospitalized with SARS-CoV-2. Our working hypothesis is that muscle mass and/or muscle strength are predictive measurements of the time until medical discharge of patients hospitalized with SARS-CoV-2

Muscle mass (via ultrasound) and muscle strength (via handgrip) of patients with SARS-CoV-2 will be assessed upon admission, medical discharge and 180 days after medical discharge. The time until medical discharge and any medical complications will be recorded. Throughout the hospitalization period, the mortality rate will also be assessed. One hundred and eighty days after medical discharge, the number of hospital readmissions, mortality rate and the use of public health services will be evaluated, to estimate the cost of each patient to the health service. Patients will be stratified according to muscle mass and strength assessed at admission. Data will be analysed using a mixed model with repeated measures assuming group (percentiles) and time (admission, medical discharge, and 180 days after medical discharge) for each dependent variable. In the event of a significant F-value, Tukey-Kramer post hoc adjustments will be used for multiple purposes. Survival rate will be examined using the Kaplan-Meier curve and analyzed using the Log-rank test (Mantel-Cox). The level of significance will be set apriori at P≤0.05.

Eligibility Criteria:
Inclusion Criteria:

* 18 Years and older ;
* hospital stay less than 48 hours;
* length of hospital stay to 48 hours no requiring invasive mechanical ventilation;

Exclusion Criteria:

* cancer in the last 5 years;
* delirium;
* cognitive deficit that impossibility the patient to read and sign the informed consent form;
* neurological disease;
* degenerative muscular disease.
Effects of Transcranial Direct Current Stimulation (tDCS) on Persistent Auditory Verbal Hallucinations in Schizophrenia

Many individuals with schizophrenia struggle with auditory verbal hallucinations (AVHs). In some cases, these AVHs can be resistant to medication treatment. Previous research has found that transcranial direct current stimulation (tDCS) can be helpful in treating symptoms in individuals with other psychiatric disorders, such as depression. This study will assess if tDCS is effective in treating AVHs in individuals with schizophrenia. tDCS is a non-invasive form of brain stimulation which uses a weak current to temporarily excite or inhibit underlying cortical regions with small electrodes placed on the scalp. tDCS has been found to improve mental processes, including attention and memory function. In addition to examining the effect of tDCS on AVHs, this study will assess the effects of tDCS on mood as well as brain electrical activity with electroencephalogram (EEG) recordings. As an additional component, participants will be invited to participate in neuroimaging. Using magnetic resonance imaging (MRI), brain activity and structure will be examined before and after tDCS. tDCS will be administered twice daily for 5 consecutive days for a total of 10 sessions. These study findings will contribute to the understanding of the impact of tDCS on AVHs, and will also increase knowledge of sound and memory/cognitive processing in individuals with schizophrenia.


Eligibility Criteria:
Patients - Inclusion Criteria:

* Primary diagnosis of schizophrenia or schizoaffective disorder
* Clinically stable (discretion of psychiatrist)
* Consistent history of AVHs over the course of illness
* \>3 AVHs per week
* Positive and Negative Syndrome Scale (PANSS) score of \>3
* Primary medications limited to one of the atypical antipsychotics (medications stabilized for 4 weeks prior to enrollment)

Patients - Exclusion Criteria:

* Experiencing an acute psychotic episode
* Current drug/alcohol dependence
* Significant medical illness \& mental retardation/learning disability
* Extra-pyramidal symptoms resulting in disordered movement
* Abnormal audiometric assessment (thresholds for pure tones \>25 dB)
* History of significant neurological issues \& head injuries/concussions resulting in loss of consciousness for \>5 minutes

Healthy Controls - Inclusion Criteria:

* In good physical health
* No history of serious mental health issues

Healthy Controls - Exclusion Criteria:

* Personal history of psychiatric disorder
* Family history of schizophrenia in first degree relatives \& history of mental health issues in first degree relatives that required extensive treatment or hospitalization
* Current/history of substance abuse
* Significant medical illness
* Extra-pyramidal symptoms resulting in movement disorder
* Abnormal audiometric assessment (thresholds for pure tones \>25 dB)
* Significant neurological issues \& head injuries/concussions resulting in loss of consciousness for \>5 minutes
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be:

At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment


Eligibility Criteria:
Inclusion Criteria:

* Participants diagnosed with locally advanced or metastatic renal cell carcinoma
* Participants with full medical information is available regarding all treatments before, during and after 1st line

Exclusion Criteria:
Factors Affecting Anesthesia Preferences of Gravid Women

The investigators aim to evaluate the preferences for anaesthesia methods of gravid women who are to deliver baby by caesarean section, the rates of general anaesthesia and regional anaesthesia, the reasons for preferences of general anaesthesia and regional anaesthesia and the factors affecting these preferences.

A questionnaire consisting of 20 questions were applied to gravid women applying for delivery by elective caesarean operation, at Ankara University Faculty of Medicine Hospital for Gynaecology and Obstetrics between February 2010 and February 2011, in order to study the anaesthesia technique the patients prefer and the reason behind their preferences. Those gravid women who accepted to take part in the study were provided information about the questionnaire and their oral and written approvals were obtained.

The questionnaire was applied to the patients in visit queue a day before or while the patients were in waiting room for caesarean operation. The gravid women who were between 26th and 40th week of their pregnancy were included in the questionnaire. Those who were taken into emergency service, those with communication problems, those whose mental conditions deter them to answer questions and those who did not want to answer the questions on the questionnaire were excluded from the study.

Eligibility Criteria:
Inclusion Criteria:

* gravid women who were between 26th and 40th week of their pregnancy were included in the questionnaire.

Exclusion Criteria:

* gravid women who were taken into emergency service, those with communication problems, those whose mental conditions deter them to answer questions and those who did not want to answer the questions on the questionnaire
Community Web Health Portal for Diabetes Prevention

This study supports the development of a diabetes prevention and control community web portal. The portal will feature an innovative personalized impediment profiling tool and reward program. The program, "Nutrition Navigation on-Line Edge," or NnoLEDGE, will be used by community consortiums for weight loss and diabetic health interventions within their communities.

The Specific Aims are:

1. Recruitment of local community organizations to participate as a community health consortium
2. Development of a comprehensive community health web portal consisting of a web portal, impediment profiler, community toolbox, and rewards system
3. Final evaluation of the system with regard to participants' attitudes and perceptions of using NnoLEDGE as a tool for weight control and diabetes prevention to determine feasibility.


Eligibility Criteria:
Inclusion Criteria:

* can read and write English

Exclusion Criteria:

* cannot read and write Engish
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

Early stage hormone receptor positive breast cancer is typically treated with adjuvant endocrine therapy in order to decrease risk of breast cancer recurrence and to improve overall survival from the disease. Typical agents used for treatment include tamoxifen and the aromatase inhibitors. In postmenopausal women, aromatase inhibitor therapy is increasingly common because it is associated with fewer long-term serious toxicities compared to tamoxifen. However, aromatase inhibitors cause arthralgias in 40-50% of patients, which can influence adherence to therapy and can lead to treatment discontinuation in a minority of cases. The mechanism underlying development of this toxicity remains unclear, and predictors of who will develop these symptoms remain undefined. Initial reports suggest that grip strength decreases during aromatase inhibitor therapy, and that body-mass index may influence development of this symptom. Therefore, this longitudinal study has been developed to determine change in grip strength over time in women treated with aromatase inhibitors and tamoxifen, as well as to identify potential associations between change in grip strength and BMI. Patient self-reported symptoms will also be collected. A total of 115 women with early stage breast cancer who are initiating therapy with either an aromatase inhibitor or tamoxifen will be enrolled.


Eligibility Criteria:
Inclusion Criteria:

* Stage 0-III breast cancer who are scheduled to receive endocrine therapy with tamoxifen or an aromatase inhibitor
* All prior surgery and chemotherapy should be complete
* Age 18 and above and postmenopausal

Exclusion Criteria:

* Major rheumatologic disorders
* Concomitant sex hormone containing drugs or Leutinizing Hormone Releasing Hormone agonist therapy
* For those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen within 4 weeks of enrollment
* For those subjects initiating treatment with tamoxifen, prior aromatase inhibitor within 4 weeks of enrollment
Prevalence Study and Identification of Factors Prognosis of Obstructive Sleep Apnea Syndrome Sleep in Pregnant Women

The exact prevalence of sleep-disordered breathing in pregnant women is not known. The results of a analysis of a small cohort of 105 pregnant women adjusted to body mass index estimate a prevalence of 8.4% in first quarter and 19.7% in the third quarter.

In this context, this study proposes to assess the prevalence of sleep-disordered breathing in pregnant women of the Private Hospital of the Loire and to identify the risks associated with these disorders by systematically proposing a polysomnography.

Pregnancy brings physical and hormonal changes and sleep is impaired by heartburn, cramps, frequent urination, fetal movements... Snoring is commonly observed in pregnant women at the end of the second and third trimester. Snoring can be a manifestation of OSAS. It has been shown that the apnea-hypopnea index (AHI) increases during pregnancy, at the third quarter. Physiological changes associated with pregnancy increase the risk of OSAS. In pregnant women, sleep deprivation leads to increased risk of gestational diabetes, high blood pressure, preeclampsia and antenatal depression, but also a risk of premature delivery or having a child with a delay in growth.

Finally, the exact prevalence of sleep-disordered breathing in pregnant women is not known. The results of a analysis of a small cohort of 105 pregnant women adjusted to body mass index estimate a prevalence of 8.4% in first quarter and 19.7% in the third quarter.

In this context, this study proposes to assess the prevalence of sleep-disordered breathing in pregnant women of the Private Hospital of the Loire and to identify the risks associated with these disorders by systematically proposing a polysomnography.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant woman aged 18 and over.
* Pregnant woman who has not yet completed her consultation of the 1st quarter.
* Woman accepting the achievement of, at most, 2 polysomnographies.
* Affiliated participant or beneficiary of a security regime social.
* Participant having been informed of the study and not objecting to the use of her data.
* Authorization to collect and use the baby's data.

Exclusion Criteria:

* Participation in another clinical study.
* Participant with protected status: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.
* Participant hospitalized without consent
Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure

Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, and has been recently indicated as a new treatment option with a strong level of recommendation (class I, level of evidence B) in the main international guidelines. Cardiovascular disease (CVD) is the most common cause of death in end stage renal disease (ESRD) patients undergoing hemodialysis (HD). Hence, treatments to improve mortality and specifically cardiovascular outcomes in this population are greatly needed. So far, no data available about the efficacy and safety of sacubitril/valsartan in ESRD patients undergoing hemodialysis, although this medication was noted to be effective and comparably well tolerable in those with estimated glomerular filtration rate(eGFR) 20 to 60 mL/min/1.73 m2 in the United Kingdom Heart and Renal Protection-III trial.

The purpose of this open label, randomized controlled study with prospective data collection is to assess the efficacy and safety of sacubitril/valsartan in maintenance hemodialysis patients with heart failure.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent obtained before any study assessment is performed.
* End stage renal disease (ESRD) patients (eGFR\<15ml/min/1.73m² as measured by the Chronic Kidney Disease Epidemiology Collaboration formula at screening) who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration.
* Chronic heart failure (NYHA class ≥ II) with reduced ejection fraction, defined as known LVEF ≤ 50%.
* Mean sitting systolic blood pressure(msSBP)≥110 mmHg.
* Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker for at least 2 weeks.
* Good compliance.

Exclusion Criteria:

* Acute renal failure with hemodialysis.
* Isolated right heart failure owing to pulmonary disease, primary cause of dyspnea due to noncardiac, non-HF causes such as acute or chronic respiratory disorders.
* Systolic blood pressure lower than 100 mmHg at screening (\<95 mmHg at the randomization visit).
* Previous history of intolerance to recommended target doses of angiotensin receptor blockers.
* Significant laboratory abnormalities at screening interfering with assessment of study drug safety or efficacy (such as serum potassium\>5.5 or \<3.5mmol/L, serum sodium\<130mmol/L or alanine aminotransferase or aspartate aminotransferase\>2 times the upper limit of the normal range)
* History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes.
* History of angioedema.
* Any medications that have potential for drug-drug interaction with LCZ696 will not be allowed during the study.
* Pregnant female.
* Use of sacubitril/valsartan prior to week-2.
Efficiency Clinical Study of NOVATEX MEDICAL Compression Garments in Patients With Ehlers-Danlos Syndrome

Objective of this study is to assess the efficiency of NOVATEX MEDICAL compression garments in patients with an Ehlers-Danlos syndrome (EDS).

To answer this objectif a comparison before/after use of compression garments will be performed for all patients.

Inclusion period: 1 year Follow-up period: 26 months Study period : 38 months

Patient visits will be organized as follow:

* V0: first visit at inclusion, clinical evaluation
* V1: 4 months after inclusion, clinical evaluation without compression garments and presure garments prescription
* V2: 8 months after inclusion, clinical evaluation with compression garments
* V3: 14 months after inclusion, clinical evaluation with compression garments
* V4: 20 months after inclusion, clinical evaluation with compression garments
* V5: 26 months after inclusion, clinical evaluation with compression garments

Only the first two visits are specific to the study to be able to compare before and after the use of compression garments. Next visits are the usual visits (every 6 months) for the use of compression garments in patients with an EDS.

Eligibility Criteria:
Inclusion Criteria:

* Patient between 15 and 60 years old
* Ehlers-Danlos Syndrome type: " classical ", " classical-like ", " hypermobile ", " arthrochalasia ", " kyphoscoliotic ", " musculocontractural " ou " myopathic ", as defined in the new international EDS classification 2017
* Patient who have never used compression garments
* Patient for whom compression garments will be prescribed at 4 months
* Patient who have dated and signed a consent form
* Patient who have understood the study
* Patient who are affiliated to French social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research

Exclusion Criteria:

* patient under guardianship or enabled to complete questionnaires
* pregnant or breastfeeding woman
* patient who presents allergy to one of compression garments components
* patient with a current medical history who promotes postural disorders
* patient with an asymptomatic "Hypermobile Sprectrum Disorder" type of EDS as defined in the new international EDS classification 2017
* patient with a current or recent (\<3months) participation in another investigational study
Nutrition of Urban-poor Children

The investigators undertook a program to promote the consumption of healthy foods and reduce the prevalence of malnutrition of children below the age of 5 years in an urban-poor community, by 10% year-on-year through nutrition education and the provision of healthy food. The main purpose of the study is to determine the impact of these nutrition intervention programs on the nutritional status of children under-5 in Selangor.

This retrospective pre-post intervention study will use data collected from 2 previous studies that were carried out between July 2020 to May 2021 (Eat Healthy Project 1.0) and March 2022 to December 2023 (Eat Healthy Project 2.0). The 2 studies had been approved by the Medical Research and Ethics Committees of University Malaya Medical Centre (UMMC) and the Ministry of Health, Malaysia and registered with the National Medical Research Registry (NMRR).

The main outcome measures were:

1. Improved dietary practices, in particular, an increase in the proportion of children who meet the minimum dietary diversity score of 5 food groups, post-intervention.
2. An increase in proportion of children consuming fruits and vegetables and a decrease in proportion of children consuming sugar-sweetened foods and beverages post-intervention.
3. A decrease in prevalence of malnutrition - underweight, wasting and stunting. The comparator will be urban-poor children attending a Child Health clinic who had received nutritional education but no provision of food supplementation.

The primary objectives:

1. To compare dietary diversity practices of children, based on the WHO 8 food groups and 24-hour dietary recall, pre- and post-intervention.
2. To compare consumption of fresh foods, sugar-sweetened foods and beverages pre- and post-intervention.

   The secondary objectives:
3. To compare the weight-for-age z-scores of children pre- and post-intervention.
4. To compare the height-for-age z-scores of children pre- and post-intervention.
5. To compare the prevalence of malnutrition: underweight, stunting and wasting pre- and post-intervention.

Eligibility Criteria:
Inclusion Criteria:

* children aged under 5 years enrolled at PPR Lembah Subang 1 or
* children aged under 5 years enrolled at the Child Health Clinic, Universiti Malaya Medical Center

Exclusion Criteria:

* Children with low birth weight (\<2.5 kg)
* Children born pre-term (\<37 weeks gestation) and
* Children with chronic illnesses or severe malnutrition.
Androgen Regulation of Priapism in Sickle Cell Disease

It is believed that when androgen (testosterone) levels are below normal there is a disturbance of normal bodily functioning that is associated with priapism in some men. Conversely, it is believed that testosterone replacement will improve the condition of priapism when the testosterone levels are brought to normal. In turn, this will also improve psychological well being in men with sickle cell disease (SCD).

The central hypothesis of this proposal is that a decline in androgen levels results in decreased action and contributes to the molecular derangements associated with priapism. Optimizing androgen status may promote regulatory molecular mechanisms that protect against priapism. This clinical trial will investigate the potential benefit of precise testosterone replacement for ameliorating priapism and improving psychological well-being in hypogonadal men with SCD.

This clinical trial aims to evaluate the efficacy of testosterone replacement therapy on the frequency of recurrent priapism in patients with SCD. The sub-hypothesis that testosterone (T) replacement to achieve serum T concentrations at a target range reduces recurrent priapism will be tested. This aim will involve subjective and objective assessments of priapism occurrences and erectile ability including priapism inventory instruments, standardized questionnaires of erectile function (EF) and quality of life, and Rigiscan™ erection monitoring in a 3.5-month pilot investigation.

Eligibility Criteria:
Inclusion Criteria:

* Ages 18-50
* History of SCD
* Episodes of prolonged penile erection in the absence of sexual interest or desire, with an average frequency of at least twice weekly, when averaged over the previous four weeks
* serum testosterone level below 550 ng/dl
* Ability to provide informed consent

Exclusion Criteria:

* Alcohol use exceeding two standard drinks daily
* Prostate conditions including prostate specific antigen (PSA) elevation (\>2.5 ng/ml)
* Known sleep apnea
* Known cirrhosis
* Enlarged and painful male breasts